Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects with Androgenic Alopecia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A ST Co., Ltd.

Criteria

Inclusion Criteria:

• Male, aged between 19 and 65 years, clinically healthy

• BMI between 18.5kg/m2 and 27kg/m2

• Clinical history of Androgenic Alopecia

Exclusion Criteria:

• Subject has any dermatological disorders of the scalp

• Subject has a history of hair transplants, hair weaves

• Subject has hypersensitivity to previously prescribed minoxidil or finasteride

• Subject who is considered inappropriate to participate in the study due to any conditions including screening results at the investigator's discretion